| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Intermediate for peptide synthesis
Fmoc-Arg(Pbf)-OH does not have a specific biological target. Its primary utility is as a chemical building block in Fmoc-based peptide synthesis. The compound serves as a protected arginine unit that can be incorporated into peptide chains while the Fmoc and Pbf groups protect the amino and guanidino groups, respectively, from unwanted reactions. Arginine is a semi-essential amino acid involved in protein synthesis and nitric oxide production, but in its protected form, the compound is not designed to interact with biological receptors or enzymes. Its value lies in its chemical properties as a synthetic intermediate. |
|---|---|
| ln Vitro |
Fmoc-Arg(Pbf)-OH does not exhibit pharmacological activity in vitro. As a protected amino acid derivative, it is a synthetic intermediate rather than a bioactive compound. In vitro studies using this compound focus on its chemical reactivity, such as its use in peptide bond formation reactions, rather than assessments of pharmacological activity. The compound may be used as a substrate in enzymatic assays to study the cleavage of protecting groups, but these are analytical applications. Its role in research is almost exclusively as a reagent for organic synthesis.
|
| ln Vivo |
Fmoc-Arg(Pbf)-OH is not a pharmacologically active compound and therefore does not have defined in vivo activity as a drug. When administered to animals, the compound would likely be metabolized to release arginine, which would then enter normal metabolic pathways. However, the compound is not used therapeutically. Its primary value remains in synthetic chemistry, where it serves as a building block for the preparation of peptides and pharmaceutical compounds.
|
| Enzyme Assay |
In vitro assays for Fmoc-Arg(Pbf)-OH are primarily focused on its chemical properties and reactivity rather than biological activity. Standard protocols in Fmoc-based solid-phase peptide synthesis involve the use of this compound as a protected arginine building block. The compound is typically dissolved in polar aprotic solvents such as DMF or DCM and coupled to a growing peptide chain on a solid support using standard peptide coupling reagents. The progress of the coupling reaction can be monitored by HPLC or TLC. The Fmoc group can be removed under basic conditions (e.g., 20% piperidine in DMF), and the Pbf group can be removed under acidic conditions (e.g., TFA in the presence of scavengers).
|
| Cell Assay |
In vitro cellular assays using Fmoc-Arg(Pbf)-OH are not commonly performed because the compound lacks intrinsic biological activity. The compound is used exclusively in synthetic chemistry applications and is not designed for cell culture studies. Its use is confined to the laboratory, where it serves as a building block for the preparation of peptides and pharmaceutical compounds.
|
| Animal Protocol |
In vivo animal studies with Fmoc-Arg(Pbf)-OH are not typically conducted, as the compound is a synthetic intermediate rather than a pharmacologically active agent. If used in vivo, the compound would be administered to animals to study the metabolism of protected amino acid derivatives. However, such studies are rare, and the compound is generally used exclusively in synthetic chemistry applications.
|
| ADME/Pharmacokinetics |
Fmoc-Arg(Pbf)-OH is not a drug candidate, and pharmacokinetic data are not available. As a protected amino acid derivative, it is designed for chemical synthesis rather than systemic administration. If administered in vivo, the compound would likely be metabolized to release arginine. The compound's pharmacokinetic properties have not been characterized.
|
| Toxicity/Toxicokinetics |
The compound is generally considered to have low toxicity, consistent with its use as a chemical reagent. The compound is typically stored at 2-8°C. Standard laboratory safety precautions, including the use of personal protective equipment, are recommended. It is not classified as a highly toxic substance, but appropriate safety measures should be followed. Inhalation, ingestion, or skin contact should be avoided.
|
| References | |
| Additional Infomation |
NBP has proven to be an ideal solvent to replace the hazardous solvent DMF in solid-phase peptide synthesis (SPPS). This paper investigates the introduction of Fmoc-Arg(Pbf)-OH (one of the most difficult amino acids to handle) into growing peptide chains. The poor performance of this amino acid stems from its formation of a completely inactive δ-lactam, leading to reduced yields and often accompanied by the formation of the corresponding dearginine peptide. This problem is exacerbated when using NBP as a solvent, likely due to its high viscosity hindering the penetration of the coupling mixture into the resin. To address this issue, we propose a strategy for the safe introduction of Fmoc-Arg(Pbf)-OH into SPPS at 45 °C with minimal excess reagent: 1.75 equivalents of the protected amino acid, 1.8 equivalents of DIC, and 1.5 equivalents of OxymaPure. The core of this strategy is in-situ activation. Specifically, Fmoc-Arg(Pbf)-OH and OxymaPure dissolved in NBP were added to the peptide resin, heated to 45°C, and then half of the DIC was added and allowed to stand for 30 minutes. Then the other half of the DIC and some additional Fmoc-Arg(Pbf)-OH were added. Throughout the process, the temperature was maintained at 45°C. This serves two purposes: first, to reduce the viscosity of NBP, thereby promoting the penetration of the coupling mixture into the resin; and second, to accelerate the coupling reaction. It is expected that this strategy can be widely used to improve the performance of solid-phase peptide synthesis (SPPS), including the industrial preparation of peptides using this method. [1]
Fmoc-Arg(Pbf)-OH (CAS 154445-77-9) is a protected amino acid derivative used as a building block in peptide synthesis. Its chemical formula is C₃₄H₄₀N₄O₇S and its molecular weight is approximately 648.78 g/mol. The compound features an Fmoc-protected amino group and a Pbf-protected guanidino group. It is the standard building block for introducing arginine residues by Fmoc SPPS. It is intended for research use only and is not for human therapeutic applications. |
| Molecular Formula |
C34H40N4O7S
|
|---|---|
| Molecular Weight |
648.7690
|
| Exact Mass |
648.261
|
| CAS # |
154445-77-9
|
| Related CAS # |
L-Arginine-N-FMOC PBF-OH-13C6
|
| PubChem CID |
11354259
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Melting Point |
132°C
|
| Index of Refraction |
1.649
|
| LogP |
6.86
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
46
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=C(C(=C(C2=C1OC(C2)(C)C)C)S(=O)(=O)NC(=NCCC[C@@H](C(=O)O)NC(=O)OCC3C4=CC=CC=C4C5=CC=CC=C35)N)C
|
| InChi Key |
HNICLNKVURBTKV-NDEPHWFRSA-N
|
| InChi Code |
InChI=1S/C34H40N4O7S/c1-19-20(2)30(21(3)26-17-34(4,5)45-29(19)26)46(42,43)38-32(35)36-16-10-15-28(31(39)40)37-33(41)44-18-27-24-13-8-6-11-22(24)23-12-7-9-14-25(23)27/h6-9,11-14,27-28H,10,15-18H2,1-5H3,(H,37,41)(H,39,40)(H3,35,36,38)/t28-/m0/s1
|
| Chemical Name |
(2S)-5-[[amino-[(2,2,4,6,7-pentamethyl-3H-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~154.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5414 mL | 7.7069 mL | 15.4138 mL | |
| 5 mM | 0.3083 mL | 1.5414 mL | 3.0828 mL | |
| 10 mM | 0.1541 mL | 0.7707 mL | 1.5414 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
